CDK4 and breast cancer: Although PD0332991 combined with endocrine therapy was approved as a first-line treatment for advanced ER+ breast cancer by the FDA (2015) and EMA (2016), no reliable biomarkers except ER status has been defined to diagnose tumors that depend on CDK4 activity and respond to CDK4/6 inhibitors6.